HSP90: A Novel Target Gene of miRNA-628-3p in A549 Cells

Lung cancer is one of the leading causes of cancer-related death in the world. MicroRNA- (miR-) 628-3p plays critical roles in many cancers, including lung cancer. We investigated how miR-628-3p affected migration and apoptosis in A549 cells. We used bioinformatics algorithms to predict the miR-628-...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2018-01, Vol.2018 (2018), p.1-10
Main Authors: Sheng, Zhenhua, Wu, Dehong, Zhou, Jia, Jiang, Fu-Sheng, Pan, Jieli, Li, Meiya
Format: Article
Language:English
Subjects:
Apoptosis
Bioinformatics
Cancer
Cancer therapies
Cell growth
Cell migration
Chromosome 3
Colorectal cancer
Deoxyribonucleic acid
DNA
Gene expression
Genes
Health aspects
Heat shock proteins
Hsp90 protein
Kinases
Luciferase
Lung cancer
Medical prognosis
Medical research
MicroRNA
miRNA
Molecular chains
Oncology
Oncology, Experimental
Pancreatic cancer
Post-transcription
Ribonucleic acid
RNA
Thyroid gland
Western blotting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is one of the leading causes of cancer-related death in the world. MicroRNA- (miR-) 628-3p plays critical roles in many cancers, including lung cancer. We investigated how miR-628-3p affected migration and apoptosis in A549 cells. We used bioinformatics algorithms to predict the miR-628-3p target gene to study the molecular mechanism by which miR-628-3p contributes to lung cancer. Then, we used the luciferase reporter assay to identify whether heat shock protein 90a (HSP90) is a direct target of miR-628-3p. Western blotting and quantitative real-time PCR showed that miR-628-3p downregulated HSP90a protein expression via a posttranscriptional mechanism. We confirm that miR-628-3p promotes apoptosis and inhibits migration in A549 cells by negatively regulating HSP90. Our results may reveal a novel strategy for lung cancer treatment.
ISSN:2314-6133
2314-6141
DOI:10.1155/2018/4149707